A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer

The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.

Inclusion Criteria:

• Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study [for example, nivolumab, pembrolizumab, atezolizumab]
• Participants must be willing to have tumor biopsies
• Participants must have adequate organ function
• Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
• Participants must be able to swallow tablets
• Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days

Exclusion Criteria:

• Participants must not have moderate or severe cardiovascular disease
• Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc)
• Participants must not have an active infection requiring treatment